Women should discuss the role of preventive therapy for breast cancer with their physicians, according to a report by the United States Preventive Services Task Force (USPSTF) in the July 2 issue of the Annals of Internal Medicine.
“We looked for randomized controlled trials of chemical prevention of breast cancer and found four in women without a previous diagnosis of that illness,” lead author Linda S. Kinsinger, MD, MPH, from the University of North Carolina at Chapel Hill, says in a news release. “Three of the four involved tamoxifen and one involved raloxifene, which the [U.S. Food and Drug Administration] has not approved [for breast cancer].”
Review of these major studies suggests that tamoxifen reduced the relative risk by nearly 50% and raloxifene by 76% for women at increased risk because of family history, early menarche, later or no childbirth, or previous breast biopsy, even if negative. Tamoxifen and raloxifene were effective only against estrogen receptor-positive tumors.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!